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ABSTRACT: Time taken to achieve a live birth is an important consideration that is central to managing patient expectations during infer-
tility treatment. However, time-related endpoints are not reported as standard in the majority of fertility-related clinical studies and there
is no internationally recognized consensus definition for such endpoints. There is, therefore, a need for meaningful discussions around the
selection of appropriate time-related treatment outcome measures for studies evaluating fertility treatments that will be relevant to diverse
stakeholders (e.g. patients, healthcare professionals, clinical scientists, authorities and industry). Here, we provide a proposal for the evalu-
ation of time-related outcome measures in fertility-related clinical studies, alongside associated definitions.
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Introduction
Time taken to achieve a live birth is an important consideration when
selecting fertility treatment, in particular because both maternal and
paternal age at the point of attempting childbearing are increasing
(ACOG, 2014; Steiner and Jukic, 2016; Hurley and DeFranco, 2017;
Bergh et al., 2019). Consequently, patients are older when they realize
a need for fertility treatment (Baird et al., 2005; Gleicher et al., 2007;
Lesthaeghe, 2010; Harris et al., 2011; Mills et al., 2011) and the biolog-
ical timeframe to achieve a live birth is shortening.
As knowledge of medically assisted reproduction (MAR) has ex-
panded, the scope to individualize fertility treatment to optimize out-
comes based on patient characteristics has increased, enabling more
patients to achieve their goal of having a child. However, once patients
enter treatment there is no guarantee of immediate success, with the
likelihood of pregnancy and subsequent live birth within a specific time
period dependent on patient characteristics and treatment decisions
(Smith et al., 2015; Chambers et al., 2017; O’Brien et al., 2017). The
likelihood of achieving a live birth increases cumulatively with each
additional attempt, and the majority of patients may now achieve
treatment success—but only if they have sufficient time for multiple
treatment cycles before natural fecundity declines markedly. In addi-
tion, there may be age cut-offs for provision of state-funded fertility
treatments. For example, the National Institute for Health and Care
Excellence (NICE) fertility guideline in the UK has a cut-off of 42 years
for state-funded IVF treatment and delays (including waiting lists) may
result in women not being eligible for treatment or for a full course of
treatment (Dolan and Rudisill, 2015). Longer treatment duration be-
fore achieving a live birth will also increase costs and reduce cost-
effectiveness both directly and indirectly, increasing the financial burden
on patients (if they are self-funding their treatment) and/or providers
(Eijkemans et al., 2017). Prolonged time in fertility treatment is stressful
(Wu et al., 2013), and any financial burden placed on patients may fur-
ther increase the stress.
These concerns, although not exhaustive, emphasize the need to
achieve a live birth in as timely a manner as possible. However,
to date, time has not been prioritized as a construct of interest in
studies of fertility treatment. Instead, the majority of commonly used
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treatment measures are based on the achievement (or not) of a fertil-
ity event of interest (e.g. pregnancy, live birth, etc.).
Here, we first discuss the evidence from the current literature on
each aspect of a time-related treatment measure, based on a system-
atic search. Then we provide suggestions on what might be the opti-
mal choice for each aspect and propose a time-related treatment
measure for use in future fertility clinical research.
Literature review of time-
related measures in fertility
studies
A systematic search of the literature was performed to understand
how time-related treatment outcomes were reported in clinical fertility
studies (Table I). In the studies identified (14 randomized controlled
trials [RCTs], 19 retrospective cohort studies and 9 prospective co-
hort studies), no single time-related outcome measure was consis-
tently used, although the most commonly cited measure was ‘time to
pregnancy’. According to International Committee Monitoring Assisted
Reproductive Technologies [ICMART], ‘time to pregnancy’ is defined
as ‘the time taken to establish a pregnancy, measured in months or in
numbers of menstrual cycles’ (Zegers-Hochschild et al., 2017).
However, this definition does not include the type of pregnancy to be
evaluated (biochemical, clinical or ongoing), or any details of the start
time point (STP) for measurement of the obstetric outcome or the
end time point (ETP) (i.e. the time at which pregnancy should be con-
firmed). There is also no guidance on how this outcome should be
evaluated (i.e. how to analyse it statistically or report it). ‘Time to
pregnancy leading to live birth’ will be included in the core outcome
set for fertility trials developed during the Core Outcome Measures
for Infertility Trials project (Duffy et al., 2018). The COMMIT project
was initiated because many different outcomes and outcome measures
were reported in RCTs evaluating interventions for infertility, and it
was proposed that this variability made it much more difficult to com-
pare and combine individual trials to inform clinical practice.
There is, therefore, no well-defined or justified treatment time mea-
sure identified that can be put forward for use in future clinical re-
search. In addition, the heterogeneity and lack of clear definitions
mean that comparison between the studies or pooling of time-related
treatment measures for meta-analysis might not be possible. This het-
erogeneity in outcomes has previously been identified as an issue for
fertility studies, with a previous review identifying many different com-
binations of numerator and denominator in RCTs evaluating IVF treat-
ment, with no single treatment measure used by a majority of studies
(Wilkinson et al., 2016). In addition, only around one-quarter of stud-
ies we identified used ‘live birth’ in their time-related treatment mea-
sure despite expert consensus specifying live birth as the most
important measure of fertility treatment success (Martins et al., 2018).
These issues highlight the need for education on suitable outcomes for
use in clinical studies, as well as on their analysis.
Time-related treatment
measures for fertility: time to
consider
The ability to compare the effectiveness of treatments with respect to a
time-related measure would enable treatment selection with the aim of
reducing time to achieve a live birth. However, the comparison of the ef-
fectiveness of different treatments is only possible if there is a standard,
widely accepted and clinically meaningful treatment measure related to
achieving a successful obstetric outcome (Maheshwari et al., 2015; Mol
et al., 2018). The availability of such an outcome measure would also
............................................................................................................................................................................................................................
Table I Summary of systematic literature search criteria.
Database(s) searched PubMed, MEDLINE, Embase
Cut-off date for publications 16 August 2019
Key words/search terms ARTs, fertility treatment, ovarian stimulation, ovulation induction, IVF, intracytoplasmic sperm injections, infertility,
subfertility/subfecundity/sterility, intrauterine insemination or intracytoplasmic sperm injection
AND
Time to or duration
AND
Birth/arrival/baby/pregnancy/delivery/conception
Excluded terms HIV, cancer, neoplasm, timelapse
Screening criteria for inclusiona A clinical study in the context of infertility (population is infertile or had clinical risk factors for infertility, e.g. fibroids,
polycystic ovary syndrome, etc.) and/or a population is undergoing fertility management or treatment (also including
fertility referral and fertility investigation), with a treatment measure that contained duration of time as an outcome
(e.g. time to pregnancy or time to live birth).
Screening criteria for exclusiona Non-clinical studies, including epidemiological incidence and prevalence studies, reviews, meta-analyses, case reports
and case series.
Results were automatically filtered to include studies in humans and publications in English, and duplicates were removed.
aBased on titles and abstracts.










































..better enable meta-analyses across studies by reducing the heterogeneity
in pooled results, and thereby increasing the power to detect differences
between treatments. This has already been done for a number of out-
comes (e.g. the ICMART definition of cumulative live birth rate), and is
particularly important in this context because a time-related measure is
unlikely to be the primary endpoint evaluated in the majority of studies.
Such studies are, therefore, unlikely to be statistically powered to detect
differences in this endpoint, with meaningful treatment differences only
observed through pooled analysis. Moreover, time to event analysis in
meta-analyses are almost exclusively underpowered at present (Stocking
et al., 2019), so more powerful analyses are imperative.
Definitions of time to
pregnancy and live birth
Defining the STP
There is only one STP that is appropriate for prospective clinical trials,
which is the time of randomization (Fig. 1). This is because randomiza-
tion is the point in all treatment groups from which variation in out-
comes could be produced. For non-randomized clinical studies,
including observational studies, the aim should be to mimic RCTs as
closely as possible. This means that a uniform STP defined at a particu-
lar point in the treatment pathway for all non-randomized studies
would imply a common study design (with respect to start of interven-
tion/treatment) for all, regardless of the research question. The STP
should, therefore, be either the time of randomization or, evoking the
idea of a target trial, the time at which you would have randomized
patients if it had been an RCT. This should coincide with the start of
intervention/treatment in the study.
Across current literature, the STP for treatment measures is fairly ho-
mogeneous, with randomization being the start point for the majority of
RCTs and, where stated, a clinical procedure or the start of MAR treat-
ment for non-RCTs. In some instances, studies evaluate a time-related
treatment measure with an STP that relies upon patient recall of, for ex-
ample, ‘first intercourse after delivery’ and ‘decision of desire to have a
child’ (Boujenah et al., 2016; Boltz et al., 2017; Cayan et al., 2017).
Defining the ETP
The ETP for any study should be selected based on the aims of the
study, the treatment being evaluated and the outcome that is
expected to be affected. As the desired outcome of fertility treatment
is live birth, this should be considered as a preferred ETP. However,
Figure 1. Summary of the proposed time-related treatment outcome measures for studies evaluating fertility treatment.
Biochemical pregnancy is defined as a pregnancy diagnosed only by the detection of beta hCG in serum or urine; clinical pregnancy is defined as a
pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy; live birth is defined as
the complete expulsion or extraction from a woman of a product of fertilization, after 22 completed weeks of gestational age which, after such sepa-
ration, breathes or shows any other evidence of life, such as heart beat, umbilical cord pulsation or definite movement of voluntary muscles, irrespec-
tive of whether the umbilical cord has been cut or the placenta is attached (Zegers-Hochschild et al., 2017). ETP, end time point; RCT, randomized
controlled trial; STP, start time point.
































































































the question becomes how to measure time to live birth in a way that
does not erroneously favour preterm births, which would result in
shorter times. Possibilities include measuring ‘time to term live birth’,
or ‘time to clinical pregnancy leading to live birth’ (Fig. 1). It should be
noted that it can only be determined whether or not a patient has had
a positive outcome with respect to this latter measure in retrospect,
since it is not known at the time of pregnancy (i.e. when there is a
positive pregnancy test), whether or not a live birth will occur.
Ongoing pregnancy rate is correlated with live birth rate and has been
suggested as a surrogate measure when live birth is not recorded (Mol
et al., 2018); however, ongoing pregnancy as an outcome does not
take into account later pregnancy losses and this may affect evaluation
of time to treatment success. Furthermore, ongoing pregnancy is not
defined in the latest ICMART Glossary (Zegers-Hochschild et al.,
2017), and is defined differently across studies, mostly corresponding
to a pregnancy marked by gestational sac with positive foetal heart ac-
tivity at 12th week of gestation (Kasius et al., 2014; Dieamant et al.,
2017; Lensen et al., 2018; Wang et al., 2019).
There may be difficulties in reliably collecting pregnancy data at fixed
times during a pregnancy outside of prospective studies, with most
clinical pregnancies detected during a standard early-pregnancy dating
scan. The inclusion of additional screening visits to a study will increase
costs and the burden of the study on the patient and the healthcare
provider. Where this is the case, we propose that researchers should
opt for the most suitable ETP for their study. This option takes into
account the fact that many investigators will be interested in evaluating
the effect of an intervention on early (upstream) reproductive out-
comes more closely related in time to the intervention under evalua-
tion. Any later or downstream effect of a specific intervention on
foetal loss, after the establishment of pregnancy with a positive foetal
heartbeat, may be influenced predominantly by other foetal or mater-
nal factors than the intervention itself, may be difficult to predict, hard
to analyse in prospective research and impossible to properly evaluate,
as the number of patients required would be too large to conduct an
RCT. In this context, the assessment of biochemical pregnancy leading
to live birth or clinical pregnancy with a positive foetal heartbeat lead-
ing to live birth may be attractive options, depending on when preg-
nancy data are collected during routine clinical practice. It is, however,
crucial that the measurement times do not systematically differ be-
tween the arms of the study, as could occur during observational stud-
ies if ultrasound appointments were booked earlier for one treatment
arm than for another. Similarly, the outcome could be biased if an un-
blinded outcome assessor measured the outcome in a more punctual
fashion for their preferred treatment. Currently, available approaches
in real-world data research may enable the evaluation of time to
achieve these proposed outcomes in large numbers of patients. These
assessments can be corrected (i.e. propensity scoring) for relevant
baseline and treatment-related confounding factors, and early-
pregnancy outcome data can be translated into (cumulative) live birth
data.
Current literature displays heterogeneity with respect to the ETPs
reported. ETPs of time-related treatment measures include ‘time to
conception/leading to live birth/ongoing pregnancy’, ‘time to (ongoing)
pregnancy/leading to live birth’ and ‘time to live birth’. In many cases,
the definition of the reproductive ETP (e.g. pregnancy or conception)
is not provided. It also should be noted that the term ‘conception’
and its derivatives were removed from the most recent ICMART
glossary, owing to consensus to use scientifically recognized definitions
such as ‘fertilization’, ‘implantation’, ‘pregnancy’ and ‘live birth’.
Evaluating the time-related treatment
measure
Although the aim of fertility treatment is to achieve a live birth, not all
patients will accomplish this goal. A common mistake is to calculate
time-related measures only in the subset of participants having a posi-
tive outcome. This induces selection bias, since it omits every partici-
pant for whom treatment did not work. A particularly poor treatment
could appear to be very promising as a result of this error. It is, there-
fore, crucial that measurements include all randomized participants, re-
gardless of whether they have a live birth or not. The follow-up times
of all participants should be included until they either have the event
or are censored. Censoring occurs when the event of interest is not
observed because the follow-up period of the study has ended, the
participant is lost to follow-up or else withdraws from the study. To
this end, we would suggest presenting a Kaplan–Meier plot or cumula-
tive incidence plot for the likelihood of achieving a clinical pregnancy
with a foetal heartbeat that results in a safe live birth over time.
Time to event may be measured in number of days (i.e. weeks or
months) or in number of menstrual or treatment cycles. Measuring
time to event in number of days provides an estimate of the time
taken to achieve the event of interest during treatment, taking into ac-
count multiple treatment cycles, the average wait times between those
cycles and any other delays that might occur during the treatment (e.g.
patient decision-making). An alternative approach is to measure time
to event more discretely, for example, in number of menstrual/treat-
ment cycles, which would account for any differences in the length of
the treatment/menstrual cycles for individual patients and would be
more applicable during counselling (see the section on patient counsel-
ling below). However, treatment cycles could vary in length based on
the stimulation strategies (e.g. long GnRH agonist versus the short
GnRH antagonist regimen) and measuring the time to event in cycles
would not take account of delays before and/or during the treatment.
Therefore, ideally, both approaches are used in combination to mea-
sure the time to event.
While it is reasonable to report numerical summaries of the time to
event in each arm of a study (e.g. the time taken for some proportion
of the group to achieve pregnancy leading to live birth) caution is
needed before applying these summaries directly to new patients. This
is because trials are generally not intended, and are thus generally not
designed, for this purpose; their inclusion criteria are not specified so
as to produce a representative sample of patients. However, relative
effectiveness of the compared treatments can be evaluated in a trial
using a ratio measure (Rothman et al., 2008). This is because relative/
ratio measures are generally reasonably stable when extrapolating
from the selected, non-representative study populations to the patient
population of interest, whereas absolute measures are not.
Hazard ratios (HR) with 95% CIs are the standard approach for
summarizing time-related treatment effects. However, analyses based
on HR require some assumptions. They assume that dropping out or
censoring is unrelated to patient prognosis (Daya, 2005) and this is un-
likely to be true for fertility treatment as patients may be more or less
likely to drop out on the basis of advice regarding their chances of a
successful outcome. Furthermore, it is known that when the treatment
































































































is stressful or physically burdensome (e.g. there is a high risk of ovarian
hyperstimulation syndrome [OHSS] owing to stimulation) the chance
of treatment postponement increases (Gameiro et al., 2012). This
means that postponement cannot be disconnected from treatment as
though it was a completely random factor (i.e. censoring in studies of
fertility treatment is unlikely to be random but rather co-influenced by
factors like risk of OHSS, poor ovarian response, and physical and/or
psychological stress) (Daya, 2005). To make meeting this assumption
more plausible, researchers should adjust for prognostic covariates in
their analysis, for example, by using Cox regression. In addition, when
calculating HR, the proportional hazards assumption is usually made.
This assumption states that the relative difference between two treat-
ment arms remains constant over time and if it does not hold true,
then a summary based on a single HR will be misleading (Herna´n,
2010).
Another approach (that may also be helpful for counselling) is to
provide the data using a summary resembling median survival time
(MST), a statistic commonly reported in oncology. MST is most com-
monly known as the time at which 50% of the cohort is expected to
achieve the desired outcome (i.e. to become pregnant and go on to
have live birth). For fertility studies, it may not be possible to calculate
the time at which 50% become pregnant, as in many studies fewer
than half the sample have live births. It might, therefore, be more ap-
propriate to report survival rates at set time points, or even to calcu-
late the time for 25% of the patients to become pregnant (i.e. time to
quartile pregnancy [TQP]). However, it is important for clinical studies
to show that outcomes might take more than one treatment cycle.
In current literature, methods commonly reported to calculate the
data for the time-related endpoint include average/mean/median, but
reported only in patients who achieve the outcome of interest (e.g.
conception, pregnancy or birth); as well as Kaplan–Meier analysis, log-
rank analysis and Cox proportional hazards analysis evaluated in the
total analysis population. In most cases, duration of follow-up for
analysis is set as a unit of time (such as months or years), although the
number of treatment cycles is another approach (Diamond et al.,
2015). The use of agreed upon definitions for evaluating interventions
that occur either outside of or during MAR treatment should enable
comparison of interventions, enabling better shared decision-making to
reduce the time to achieving a live birth. The question of how to
make individualized treatment recommendations, for example, by
combining the effect estimate from an RCT with a prediction model-
ling approach, is the subject of ongoing research (Kent et al., 2018).
Use of time-related measures
in counselling
While time-related measures are of value to the design of research in
this field, it is ultimately patients who will be an important source of
demand for time-related information when balancing considerations in
treatment selection and decision-making. Time to event estimates
could serve as a reference for patients matching the eligibility criteria
of the studies. They may also be utilized in patient counselling with
regards to setting expectations and facilitating shared treatment
decision-making, taking into account the duration of treatment as one
of the aspects to be considered.
However, conveying clinical data to patients brings inherent chal-
lenges. Language that the patient will understand should be used when
communicating outcome data, including discussion of the applicability
of the data to clinical practice. For example, the meaning and relation
to time of HR may be difficult to convey. As an alternative, a summary
value, such as MST, could be useful, but may also be misleading and
so needs to be renamed for use in fertility treatment counselling. Care
should also be taken in the presentation of other measures, such as
TQP, which might encourage a single cycle view of fertility treatment.
The most valuable information to the patient regarding the length of
the treatment should account for the ultimate goal of MAR—live birth.
Multiple studies have demonstrated improvement in early or midway
reproductive outcomes (i.e. positive biochemical pregnancy test, clini-
cal pregnancy, ongoing pregnancy) with one intervention compared
with the other; however, these failed to demonstrate the improve-
ment in live birth. To this end, ‘time to (term) live birth’ or ‘time to
pregnancy leading to live birth’ is encouraged as the preferred time-
related treatment outcome.
When counselling patients on ‘time to pregnancy leading to live
birth’, our proposals need to consider common decision-making heu-
ristics that may bias understanding of probability/risk information (e.g.
framing and anchoring effects, poor affective forecasting) (Elwyn et al.,
2011). It is also known that patients systematically over-evaluate their
chances of pregnancy relative to what doctors predict, even when per-
sonal characteristics would predict poorer prognosis (e.g. age, years in-
fertile) (Kowalcek et al., 2003). Therefore, future research is needed
to evaluate how best to present such information to patients in a way
to minimize bias in clinics but also to ensure knowledgeable and in-
formed patient choice.
Conclusion
Currently, there is no standard definition of a time-related treatment
measure for use in clinical studies evaluating fertility treatment and
there is no consistency in the evaluation of these endpoints. We have,
therefore, proposed time-related treatment measures (Fig. 2), which
should be a call-to-action to ensure appropriate statistical analyses are
used when evaluating time-related endpoints in clinical trials. Critically,
our proposals for this time-related measure should be refined based
on further discussions, and robustly validated by methodologists in
regards to design and analysis, as these can be particularly complex
and challenging. Overall, the topic of time-related treatment measures
for fertility-related clinical studies is important for healthcare professio-
nals and patients, and further discussion is warranted to validate ap-
propriate measures for future use.
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Figure 2. Key points on the proposed time-related treatment measures for use in future fertility clinical research.
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